This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

Shahzad Raza, MD, discusses the phase 2 RedirecTT-1 study which investigated the combination of talquetamab and teclistamab for treating patients with relapsed/refractory multiple myeloma complicated ...

ERA Congress 2025 marked a pivotal moment in nephrology this year, bringing together over 9,000 global experts to explore ...